# Imbria Pharmaceuticals

> Private, clinical-stage biopharmaceutical company (Boston area) developing novel cardiovascular
> therapies that target cardiac energy metabolism. Lead candidate: ninerafaxstat, a first-in-class
> partial fatty acid oxidation (pFOX) inhibitor.

Imbria Pharmaceuticals is a therapeutics developer, not a software vendor.

**There is no public API.** As of 2026-08-22, Imbria publishes no API, no developer portal, no
documentation or API reference, no SDK or client library, no OpenAPI/AsyncAPI/GraphQL contract,
no MCP server, no A2A agent card, and no `/.well-known/` documents. `imbria.com` is a WordPress
site; the only machine-readable surface it exposes is the WordPress core REST API at
`https://imbria.com/wp-json/`, which is default CMS infrastructure shipped by WordPress rather
than an API product Imbria designed, documented or supports. It is not treated as a developer
program here and no contract is recorded for it.

## Science and pipeline

- [Science & Pipeline](https://imbria.com/science-pipeline/): overview of Imbria's cardiac energy
  metabolism approach.
- [Ninerafaxstat](https://imbria.com/science-pipeline/ninerafaxstat/): partial fatty acid
  oxidation (pFOX) inhibitor that shifts myocardial substrate utilization toward glucose
  oxidation, generating more ATP per unit of oxygen consumed and improving cardiac metabolic
  efficiency without affecting heart rate, rhythm, ejection fraction or blood pressure.
- [Non-obstructive hypertrophic cardiomyopathy (nHCM)](https://imbria.com/science-pipeline/nhcm/):
  lead indication. Ninerafaxstat holds FDA Orphan Drug Designation for symptomatic nHCM and is in
  the global FORTITUDE-HCM Phase 2b trial (NCT07023614). No approved treatments exist today.
- [HFpEF](https://imbria.com/science-pipeline/hfpef/): heart failure with preserved ejection
  fraction; a cardiometabolic HFpEF Phase 2b is planned.
- [Clinical Trials](https://imbria.com/science-pipeline/clinical-trials/) and
  [Expanded Access Policy](https://imbria.com/science-pipeline/clinical-trials/expanded-access/).
- [Publications & Presentations](https://imbria.com/science-pipeline/publications-presentations/).

## Company

- [Home](https://imbria.com/)
- [Our Story](https://imbria.com/our-story/) — mission, team, board.
- [Investors](https://imbria.com/our-story/investors/) — RA Capital, SV Health Investors, Deep
  Track Capital, Catalio Capital Management, AN Ventures, Cytokinetics.
- [Careers](https://imbria.com/careers/)
- [Contact](https://imbria.com/contact/)

## News

- [Press Releases](https://imbria.com/investors-media/press-releases/)
- [RSS feed](https://imbria.com/feed/)

## Legal

- [Terms of Use](https://imbria.com/terms-of-use/)
- [Privacy Policy](https://imbria.com/privacy-policy/)

## Optional

- [LinkedIn](https://www.linkedin.com/company/imbria/)
- [API Evangelist profile](https://apis.io/provider/imbria-pharmaceuticals/) — independent
  third-party profile; not operated by Imbria Pharmaceuticals.